Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
$25.79+0.55%
报价 2026-11-06
市值
$13.34B
EV
$20.17B
PE (TTM)
–
预期 PE (FY2026)
12.3x
52 周区间距高点 -9.0%
$15.80$28.35
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 1.94 → 2.04（1.0x） | 12.7 |
| FY+32028-12 | 1.1x | 1.94 → 2.17（1.1x） | 11.9 |
毛利率 30% · TTM 收入 $11611M · 基数 EPS 1.94（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BAXBaxter International Inc. | $13.34B | +0.5% | +5.8% | 33.4% | – | 25.2x | 13.3x | |
| DVADaVita Inc. | $12.04B | -1.8% | +4.8% | 30.9% | 17.5x | 9.3x | 11.8x | |
| RGENRepligen Corporation | $11.09B | +3.0% | +15.8% | 53.1% | 233.1x | 56.2x | 87.9x | |
| AVTRAvantor, Inc. | $10.48B | +2.2% | +2.2% | 31.5% | 30.9x | 15.1x | 23.9x | |
| QGENQiagen N.V. | $10.39B | -1.0% | +2.8% | 63.6% | 25.8x | 16.0x | 23.2x | |
| BIOBio-Rad Laboratories, Inc. | $10.25B | +3.4% | +0.1% | 51.9% | 9.4x | 9.6x | 27.2x | |
| MDGLMadrigal Pharmaceuticals, Inc. | $9.23B | -0.1% | +57.5% | 94.1% | – | – | – | |
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| HIMSHims & Hers Health, Inc. | $5.85B | +8.1% | +36.5% | 63.8% | – | – | 73.5x | 高增长 |
| 同行中位数 | – | – | +6.8% | 52.5% | 23.9x | 13.1x | 25.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.98B | $2.96B | $2.7B | $2.97B | $2.84B | $2.81B | $2.63B | $2.75B |
| Gross Margin | 33.4% | 34.9% | 33% | 19.4% | 33.5% | 35.3% | 32.8% | 34.8% |
| Operating Margin | 7.6% | 7.3% | 2.4% | -24.5% | 6.1% | 6.8% | 2.2% | -15.8% |
| Net Income | $294M | $126M | $-15M | $-1.13B | $-46M | $91M | $126M | $-512M |
| Diluted EPS | 0.57 | 0.24 | -0.03 | -2.16 | -0.09 | 0.18 | 0.25 | -1 |
| Operating Cash Flow | $558M | $285M | $213M | $584M | $237M | $217M | $-193M | $488M |
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。